Department of Nutrition and Dietetics, Faculty of Health Sciences, Bahcesehir University, Istanbul, Turkey.
Department of Internal Medicine, Helios Hospital Schleswig, Academical Educational Hospital of Luebeck and Kiel Universities, Schleswig, Germany.
Eur J Gastroenterol Hepatol. 2021 Dec 1;33(1S Suppl 1):e390-e394. doi: 10.1097/MEG.0000000000002110.
There is still no approved pharmacotherapy for metabolic (dysfunction) associated fatty liver disease (MAFLD). Although dietary and lifestyle modifications for weight loss remain the mainstay for disease management, the association between macro- and micronutrients and fibrosis stage in patients with MAFLD remains unclear. This study was undertaken to address this issue.
This is a retrospective analysis of prospectively collected data from patients in whom MAFLD was diagnosed with vibration controlled transient elastography. Steatosis was defined by a controlled attenuation parameter ≥238 dB/m, whereas a liver stiffness measurement ≥11 kPa was considered to indicate advanced fibrosis.
The study sample consisted of 106 patients with MAFLD (mean age 49 ± 10 years, 52 men and 54 women). Among the different micro- and macronutrients tested, only the dietary intake of cholesterol and saturated fatty acid (SFA) was independently associated with the presence of advanced fibrosis.
Our findings suggest that cholesterol/SFA-restricted dietary regimens - as exemplified by the traditional Mediterranean diet - may reduce the risk of advanced fibrosis in patients with MAFLD.
目前尚无针对代谢（功能）相关脂肪性肝病（MAFLD）的批准药物治疗方法。尽管减肥的饮食和生活方式改变仍然是疾病管理的主要方法，但 MAFLD 患者的宏量和微量营养素与纤维化分期之间的关系仍不清楚。本研究旨在解决这一问题。
这是一项使用振动控制瞬时弹性成像对 MAFLD 患者进行前瞻性数据收集的回顾性分析。通过控制衰减参数≥238dB/m 来定义脂肪变性，而肝脏硬度测量值≥11kPa 则被认为存在晚期纤维化。
本研究样本包括 106 例 MAFLD 患者（平均年龄 49±10 岁，52 名男性和 54 名女性）。在所测试的不同微量和宏量营养素中，只有胆固醇和饱和脂肪酸（SFA）的膳食摄入量与晚期纤维化的存在独立相关。
我们的研究结果表明，胆固醇/SFA 限制饮食方案 - 如传统的地中海饮食 - 可能会降低 MAFLD 患者发生晚期纤维化的风险。
